Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Research & Development (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Research & Development for 10 consecutive years, with $1.0 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 99.47% to $1.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $547.7 million through Dec 2025, down 21.53% year-over-year, with the annual reading at $750.0 million for FY2025, 7.45% up from the prior year.
  • Research & Development for Q4 2025 was $1.0 million at Ultragenyx Pharmaceutical, down from $216.2 million in the prior quarter.
  • The five-year high for Research & Development was $237.3 million in Q3 2022, with the low at $1.0 million in Q4 2025.
  • Average Research & Development over 5 years is $154.8 million, with a median of $163.1 million recorded in 2024.
  • The sharpest move saw Research & Development skyrocketed 490.07% in 2021, then plummeted 99.47% in 2025.
  • Over 5 years, Research & Development stood at $123.0 million in 2021, then soared by 38.85% to $170.8 million in 2022, then decreased by 6.26% to $160.1 million in 2023, then rose by 17.36% to $187.9 million in 2024, then tumbled by 99.47% to $1.0 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $1.0 million, $216.2 million, and $164.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.